Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review)

Published:2022-09-20 Issue:5 Volume:61 Page:
ISSN:1019-6439
Container-title:International Journal of Oncology
language:
Short-container-title:Int J Oncol

Author:

Ma Xiaoran¹,Wu Jibiao²,Wang Bin³,Liu Cun⁴,Liu Lijuan⁵,Sun Changgang⁴

Affiliation:

1. College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, P.R. China

2. College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, P.R. China

3. College of Basic Medicine, Qingdao University, Qingdao, Shandong 266073, P.R. China

4. College of Traditional Chinese Medicine, Weifang Medical University, Weifang, Shandong 261041, P.R. China

5. Department of Oncology, Weifang Traditional Chinese Hospital, Weifang, Shandong 261041, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Reference184 articles.

1. Regulation of PD-L1: A novel role of pro-survival signalling in cancer;Chen;Ann Oncol,2016

2. Cancer immunotherapy comes of age;Mellman;Nature,2011

3. Programmed death ligand-1 (PD-L1) expression in the programmed death receptor-1 (PD-1)/PD-L1 blockade: A key player against various cancers;Guan;Arch Pathol Lab Med,2017

4. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion;Dong;Nat Med,2002

5. Comparative analysis of predictive biomarkers for PD-1/PD-L1 inhibitors in cancers: Developments and challenges;Yang;Cancers,2021

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy;Journal of Translational Medicine;2024-08-09

2. Predictive value of circulating immune cell changes in response to PD-1 blockade and TKI therapy in patients with hepatocellular carcinoma;Clinics and Research in Hepatology and Gastroenterology;2024-08

3. The role of the immunosuppressive PD-1/PD-L1 checkpoint pathway in the aging process and age-related diseases;Journal of Molecular Medicine;2024-04-11

4. A new strategy for immunotherapy of microsatellite‐stable (MSS)‐type advanced colorectal cancer: Multi‐pathway combination therapy with PD‐1/PD‐L1 inhibitors;Immunology;2024-03-22

5. PD-L1 Expression and Tumour Microenvironment Patterns in Resected Non-Small-Cell Lung Cancer;Medicina;2024-03-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3